[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571046":3},{"organization":4,"outcomesModule":7,"designInfo":69,"detailedDescription":80,"studyPopulation":68,"armGroups":81,"interventions":94,"overallOfficials":102,"centralContacts":107,"locations":113,"responsibleParty":131,"collaborators":68,"id":133,"slug":68,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":68,"enrollmentInfo":142,"targetDuration":68,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":155,"whyStopped":68,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"University of Santiago de Compostela","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":68},[9],{"measure":10,"description":11,"timeFrame":12},"Change in probing depth","The change in probing depth (quantitative dependent variable) at 12 months will be measured in millimeters as the distance from the mucosal margin to the bottom of the peri-implant pocket, using a millimetric CP15 UNC Hu-Friedy probe. The change in probing depth will also be measured at 3 and 6 months.","From enrollment to the end of treatment at 12 months",[14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65],{"measure":15,"description":16,"timeFrame":12},"Recession","Distance from the implant shoulder to the margin of the peri-implant mucosa, measured in millimeters using a millimetric CP15 UNC Hu-Friedy probe. If the margin of the peri-implant mucosa is located apically to the implant shoulder, it will be recorded as a positive value (+); conversely, if the margin of the peri-implant mucosa is located coronally to the implant shoulder, it will be recorded as a negative value (-)",{"measure":18,"description":19,"timeFrame":12},"Clinical attachment level","Distance from the implant shoulder to the bottom of the peri-implant pocket (probing depth + recession) measured in millimeters using a millimetric CP15 UNC Hu-Friedy probe",{"measure":21,"description":22,"timeFrame":12},"Bleeding index","0: absent bleeding \u002F 1: present bleeding",{"measure":24,"description":25,"timeFrame":12},"Plaque index","0: absent plaque \u002F 1: present plaque",{"measure":27,"description":28,"timeFrame":12},"Width of the keratinized mucosa","From the peri-implant mucosal margin to the mucogingival line measured in millimeters using a millimetric CP15 UNC Hu-Friedy probe",{"measure":30,"description":31,"timeFrame":12},"Changes in radiographic bone level","Distance from the implant shoulder to the apical extent of the bone defect in mesial, distal, and total (calculated as the average of mesial and distal distances) of each implant on standardized periapical radiographs following the long cone paralleling technique with individualized positioning devices.",{"measure":33,"description":34,"timeFrame":12},"Change in bacterial load","The levels of the following pathogens will be determined: Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, Prevotella intermedia, Parvimonas micra, Fusobacterium nucleatum, Campylobacter rectus, Eikenella corrodens, Candida albicans and the total bacterial count.",{"measure":36,"description":37,"timeFrame":12},"Implant survival","Maintenance of each implant's function included in the study",{"measure":39,"description":40,"timeFrame":12},"Endothelial function","Measured by endothelium-dependent vasodilation in the brachial artery using a vascular ultrasound",{"measure":42,"description":43,"timeFrame":12},"Subclinical atherosclerosis","Measured by the intima-media thickness of the carotid artery using a vascular ultrasound",{"measure":45,"description":46,"timeFrame":12},"Concentration of inflammatory cytokines biomarkers","The predetermined biomarkers to be analyzed include a multiplex inflammatory panel (IL-1β, IL-12p70, IFN-γ, IL-6, IL-10, IL-8, TNF-α), measured in pg\u002FmL",{"measure":48,"description":49,"timeFrame":12},"Concentration of endothelial activation\u002Finjury markers","Endothelial activation\u002Finjury markers (E-selectin, P-selectin, thrombomodulin, ICAM-1, ICAM-3, VCAM-1), measured in ng\u002FmL",{"measure":51,"description":52,"timeFrame":12},"Concentration of serum C-reactive protein","C-reactive protein (CRP), measured in mg\u002FL using Meso Scale assays (pro-inflammatory 7-PLEX, Vascular Injury Panel I, and V-PLEX Panel II)",{"measure":54,"description":55,"timeFrame":12},"Concentration of serum amyloid A","Serum amyloid A (SAA), measured in µg\u002FmL using Meso Scale assays (pro-inflammatory 7-PLEX, Vascular Injury Panel I, and V-PLEX Panel II)",{"measure":57,"description":58,"timeFrame":12},"Concentration of circulating blood cells","Circulating blood cells will be measured in 10³\u002FµL",{"measure":60,"description":61,"timeFrame":12},"Concentration of high-sensitivity CRP","High-sensitivity CRP (hs-CRP) will be assessed using ELISA, in mg\u002FL",{"measure":63,"description":64,"timeFrame":12},"Rate of lipid fractions","Lipid fractions (triglycerides, total cholesterol, HDL, LDL) will be assessed in mg\u002FdL using standard biochemical methods",{"measure":66,"description":67,"timeFrame":12},"Treatment success","Treatment success will be established as achieving a probing depth ≤5 mm, without bleeding in more than one point, and without suppuration, in each implant included in the study.",null,{"allocation":70,"interventionModel":71,"interventionModelDescription":68,"primaryPurpose":72,"observationalModel":68,"timePerspective":68,"maskingInfo":73},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":74,"maskingDescription":68,"whoMasked":75},"QUADRUPLE",[76,77,78,79],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Peri-implantitis is defined as the pathological alteration associated with plaque that occurs in the tissues surrounding dental implants, characterized by inflammation of the peri-implant mucosa and subsequent progressive loss of supporting bone. Bacterial colonization of the implant surface in a susceptible subject is considered the primary etiological factor of this pathology. Case series and clinical trials have demonstrated an additional benefit when using systemic antibiotics such as ornidazole or metronidazole after non-surgical treatment of peri-implantitis.\n\nThe rationale for conducting this clinical trial lies in the lack of randomized studies that have tested the non-surgical treatment of peri-implantitis with shorter antibiotic regimens and their potential impact on systemic health.\n\nThe primary objective of this randomized clinical trial is to evaluate the change in probing depth at 12 months in patients with peri-implantitis, assessing the influence of systemic antibiotic (azithromycin) as an adjunct to the non-surgical treatment of peri-implantitis.\n\nThe secondary objective is to assess clinical, radiographic, and microbiological changes at 3, 6, and 12 months. Additionally, systemic biomarkers, complete blood count, glycosylated hemoglobin and creatinine will be evaluated at day 7, and 3, 6, and 12 months. Endothelial function (endothelium-dependent vasodilation measured in the brachial artery) and subclinical atherosclerosis (measurement of carotid artery intima-media thickness) will be evaluated at 12 months.\n\nDesign: This research is designed as a 1-year randomized controlled trial (RCT), with 2 parallel groups, triple-blind, and placebo-controlled.\n\nPopulation: Patients who come to the Periodontology Department, Faculty of Dentistry, University of Santiago de Compostela with dental implants presenting pathology.\n\nTreatment Groups: Study group: patients treated by non-surgical treatment in conjunction with systemic azithromycin. Control group: patients treated by non-surgical treatment in conjunction with a placebo. Subjects will be randomly assigned to one of the two treatment groups.\n\nRandomization: A balanced randomization by blocks will be performed to avoid imbalances between the two treatment groups. The randomization outcome will be stored in envelopes along with the antibiotic or placebo containers that will be delivered on the day of the non-surgical treatment.\n\nTreatment: After the diagnosis of peri-implantitis, patients were instructed in oral hygiene and motivation was reinforced. After that, one session of nonsurgical treatment consisting of supra- and submucosal mechanical debridement using ultrasound with a metal periodontal tip was performed with concomitant irrigation of chlorhexidine of 0.12%. The tip removed granulation tissue and also touched the implant surface. After that, a steel curette Columbia 4R\u002F4L was used to remove granulation tissue and minor mucosa curettage. If oral hygiene was not allowed by prosthetic design, a contour correction was made. Immediately after treatment, patients were prescribed to apply a chlorhexidine gel in the area 2 times a day for 2 weeks and depending on the result of randomization, the exact number of antibiotic or placebo tablets to be taken by the patient in the following days will be provided.",[82,88],{"label":83,"type":84,"description":85,"interventionNames":86},"Azithromycin 500 mg","ACTIVE_COMPARATOR","Systemic antibiotic: Azithromycin 500 mg every 24 hours for 3 days",[87],"Drug: Azithromcyin",{"label":89,"type":90,"description":91,"interventionNames":92},"Placebo","PLACEBO_COMPARATOR","Same shape, size and dosage as test",[93],"Other: Placebo",[95,100],{"type":96,"name":97,"description":98,"armGroupLabels":99,"otherNames":68},"DRUG","Azithromcyin","Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.",[83],{"type":6,"name":89,"description":98,"armGroupLabels":101,"otherNames":68},[89],[103],{"name":104,"affiliation":105,"role":106},"Juan Blanco Carrión","Universidade de Santiago de Compostela","PRINCIPAL_INVESTIGATOR",[108],{"name":109,"role":110,"phone":111,"phoneExt":68,"email":112},"Antonio Liñares González","CONTACT","+34 626492454","antonio@antoniolinares.com",[114],{"facility":115,"status":68,"city":116,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":126,"contacts":127},"Department of Surgery and Medical-Surgical Specialties, Teaching and Research Unit in Periodontology. Faculty of Medicine and Dentistry, University of Santiago de Compostela.","Santiago de Compostela","A Coruña","15782","Spain","ES",{"type":122,"coordinates":123},"Point",[124,125],-8.54569,42.88052,{"lat":125,"lon":124},[128,130],{"name":109,"role":110,"phone":129,"phoneExt":68,"email":112},"626492454",{"name":104,"role":110,"phone":68,"phoneExt":68,"email":68},{"type":106,"investigatorFullName":104,"investigatorTitle":132,"investigatorAffiliation":5,"oldNameTitle":68,"oldOrganization":68},"Associate Professor","100571046",false,"NCT06715150","Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo","NON-SURGICAL TREATMENT of PERI-IMPLANTITIS with or WITHOUT SYSTEMIC AZITHROMYCIN: a RANDOMIZED CLINICAL TRIAL in HUMANS","NSTP","Inclusion Criteria:\n\n* older than 18 years;\n* absence of systemic pathology contraindicating treatment;\n* presence of at least 1 implant diagnosed with peri-implantitis: presence of bleeding on probing, probing depth ≥6 mm, and radiographic bone level ≥3 mm apical to the most coronal portion of the intraosseous part of the implant;\n* absence of implant mobility;\n* patients without periodontitis or with treated periodontitis;\n* patients who understand the treatment and are willing to comply with it by providing written informed consent.\n\nExclusion Criteria:\n\n* smokers ≥10 cigarettes\u002Fday;\n* diabetic patients (HbA1c level ≥6,5%);\n* pregnant or breastfeeding women;\n* use of antibiotics, corticosteroids, and\u002For immunosuppressive treatment in the 3 months prior to the start of the study;\n* allergy to azithromycin;\n* patients with a history of bisphosphonate treatment;\n* chronic consumption of non-steroidal anti-inflammatory drugs;\n* bone loss exceeding the apex of the implant;\n* prosthesis that does not allow access to peri-implantitis treatment","ALL","18 Years",{"count":143,"type":144},52,"ESTIMATED","INTERVENTIONAL",[147],"PHASE4","The primary objective of this study is to evaluate the change in probing depth in patients with peri-implantitis, assessing the influence of systemic antibiotic (azithromycin) adjunctive to non-surgical treatment at 12 months. The secondary objective is to assess clinical, radiographic, microbiological, and systemic changes at 3, 6, and 12 months.\n\nThis study is designed as a placebo-controlled, randomized, triple-blind clinical trial in subjects diagnosed with peri-implantitis.\n\nThe treatment will consist of debridement of the implant surface and curettage of the pocket epithelium. The control group will receive placebo (1 placebo tablet per day for 3 days), and the test group will receive systemic azithromycin 500 mg per day for 3 days (1 tablet of 500 mg azithromycin per day for 3 days).",[150],"Peri-implantitis",[152,153,154],"Non-surgical treatment","Azithromycin","Systemic antibiotic","NOT_YET_RECRUITING","2024-12-04",{"date":158,"type":159},"2024-12-10","ACTUAL",{"date":161,"type":144},"2025-01-10",{"date":163,"type":144},"2027-01-10",{"name":5,"class":6},1]